Protocols
10 protocol(s) meet the specified criteria
Disease Site: Multiple Myeloma
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
54767414SMM3001A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple MyelomaOpen
A061202A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as part of first line therapy.Open
ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
BMT-CTN-1302Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple MyelomaOpen
INCB-18424-365A Phase III Randomized Open-Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH 3)Open
KCP-330-017STOMPKCP-330-017 STOMP A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple MyelomaOpen
LCCC1603-ATLPhase I Study of the Administration of Autologous CAR-T Cells Targeting the CD138 Antigen for Relapsed / Refractory Multiple MyelomaOpen
NP39403NP39403-Open label, Multicenter, Dose escalation/expansion phase 1b study to evaluate safety, pharmacokinetics and activity of BET inhibitor R06870810, given as mono and combination therapy to patients with advanced Multiple MyelomaOpen
S1702-CIRBS1702, CIRB " A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for patients with previously treated Al AmyloidosisOpen